Recurrence Rate of Cervical Cancer in Jakarta

Main Article Content

Gatot Purwoto
Fara Vitantri
Sigit Purbadi
Yuri Feharsal
Lisa Novianti
Laurensia Scovani


Histopathology, Radical Hysterectomy, Recurrence, Cervical cancer


Introduction: Cervical cancer is one of the ten most commonly diagnosed cancer in the world population. It is estimated there are around 570.000 new cases, with 3.3% deaths in 2018. The recurrence rate for cervical cancer ranges from 8% to 26% and usually appears within 2-3 years after the first treatment. The recurrence rate of cancer is one quality service in healthcare.; thus, the authors decide to evaluate this issue. Materials and Methods: This multicenter and retrospective study reporting 262 patients of all stage cervical cancer who met inclusion criteria from 2015 to 2019 in national reference teaching hospitals in Jakarta, Indonesia. Patients were treated with radical hysterectomy, radiation, and chemotherapy and observed for five years period. Univariate and multivariate analyses were performed to investigate the recurrence of cervical cancer. Results: The recurrence rate over all stages after primary treatment is 21.4%. The recurrence rate early stage and advanced stage is 20% and 38%, respectively. Univariate and multivariate analysis revealed parity, cancer stage, tumor size, histotype, and differentiation affecting the recurrence of the disease. Cox multivariate modeling determined the significant factors are parity (Hazard Ratio (HR) = 0.5, p-value <0.01), cancer stage (Hazard Ratio (HR) = 1.6, p-value 0.013), tumor size (Hazard Ratio (HR) = 2.08, p-value 0.018), histotype (Hazard Ratio (HR) = 2.6, p-value <0.01), and differentiation (Hazard Ratio (HR) = 0.5, p-value 0.01). Conclusion: The recurrence rate of cervical cancer is related to the cancer stage. The higher cancer stage resulted in a higher recurrence rate.

Abstract 221 | PDF Downloads 127


1. WHO. Cancer Today [Internet]. 2018 [cited 2020 Nov 13]. Available from:
2. WHO. Indonesia Fact Sheets. Int Agency Res Cancer Globocan. 2019;256(Cervix uteri: WHO):2018–9.
3. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–82.
4. INASGO. Indonesian Society of Gynecologic Oncology National Data [Internet]. [cited 2020 Nov 13]. Available from:
5. Salani R, Khanna N, Frimer M, Bristow RE, Chen L may. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol. 2017;146(1):3–10.
6. Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M. Follow-up for women after treatment for cervical cancer: A systematic review. Gynecol Oncol. 2009;114(3):528–35.
7. Faubion SS, Maclaughlin KL, Long ME, Pruthi S, Casey PM. Surveillance and Care of the Gynecologic Cancer Survivor. J Women’s Heal. 2015;24(11):899–906.
8. Duyn A, Van Eijkeren M, Kenter G, Zwinderman K, Ansink A. Recurrent cervical cancer: Detection and prognosis. Acta Obstet Gynecol Scand. 2002;81(4):351–5.
9. Mackay HJ, Wenzel L, Mileshkin L. Nonsurgical Management of Cervical Cancer: Locally Advanced, Recurrent, and Metastatic Disease, Survivorship, and Beyond. Am Soc Clin Oncol Educ B. 2015 May;176(35):e299–309.
10. Hanprasertpong J, Jiamset I. Late Recurrence of Early Stage Cervical Cancer more than 3 Years after Radical Hysterectomy with Pelvic Node Dissection. Oncol Res Treat. 2017;40(5):270–6.